Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2014; 20(9): 2267-2278
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2267
Table 4 Studies of cryoablation in pancreatic ductal adenocarcinoma
StudynPatientsStudyOutcomeComplications
Patiutko et al[25] (non-English article)30Locally advanced PDACCombination of cryosurgery and radiationPain relief and improvement in performance status: 30/30Not reported
Kovach et al[52]9Unresectable PDACPhase I study of intraoperative cryoablation under US guidance. Four had concurrent gastrojejunostomy7/9 discharged with non-intravenous analgesia and 1/9 discharged with no analgesiaNo complications reported
Li et al[53] (non-English article)44Unresectable PDACIntraoperative cryoablation under US guidanceMedian overall survival: 14 mo40.9% (18/44) had delayed gastric empting. 6.8% (3/44) had a bile and pancreatic leak
Wu et al[54] (non-English article)15Unresectable PDACIntraoperative cryoablation under US guidanceMedian overall survival: 13.4 mo1/15 patients developed a bile leak
Yi et al[55] (non-English article)8Unresectable PDACIntraoperative cryoablation under US guidanceNot reported25% (2/8) developed delayed gastric emptying
Xu et al[26]38Locally advanced PDAC, 8 had liver metastasesIntraoperative or percutaneous cryoablation under US or CT guidance + (125) iodine seed implantationMedian overall survival: 12 mo. 19/38 (50.0%) survived more than 12 moAcute pancreatitis: 5/38 (one has severe pancreatitis)
Xu et al[56]49Locally advanced PDAC, 12 had liver metastasesIntraoperative or percutaneous cryoablation under US or CT guidance and (125) iodine seed implantation. Some patients also received regional celiac artery chemotherapyMedian survival: 16.2 mo. 26 patients (53.1%) survived more than 12 moAcute pancreatitis: 6/49 (one had severe pancreatitis)
Li et al[57]68Unresectable PDAC requiring palliative bypassRetrospective case-series of intraoperative cryoablation under US guidance, followed by palliative bypassMedian overall survival: 30.4 mo (range 6-49 mo)Postoperative morbidity: 42.9%. Delayed gastric emptying occurred in 35.7%
Xu et al[58]59Unresectable PDACIntraoperative or percutaneous cryotherapyMedian survival: 8.4 mo. Overall survival at 12 mo: 34.5%Mild abdominal pain: 45/59 (76.3%) Major complications (bleeding, pancreatic leak): 3/59 (5%) 1/59 developed a tract metastasis
Niu et al[29]36 (CT) 31 (CIT)Metastatic PDACIntraoperative cryotherapy (CT) or cryoimmunotherapy (CIT) under US guidanceMedian overall survival in CIT: 13 mo CT: 7 moNot reported